Pioneering gene therapy patients stay on track, boosting Spark’s hemophilia B program – Endpoints News
Endpoints News |
Pioneering gene therapy patients stay on track, boosting Spark's hemophilia B program
Endpoints News After rattling investors with early signs of an immune reaction in a couple of cases as well as an unexpected infusion for a suspected knee bleed, Spark Therapeutics $ONCE says that its early Phase I/II study for its hemophilia B gene therapy is … |
